96 related articles for article (PubMed ID: 21249721)
1. MET inhibitors: translating from bench to bedside.
Mayor S
Lancet Oncol; 2011 Jan; 12(1):14. PubMed ID: 21249721
[No Abstract] [Full Text] [Related]
2. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
3. MET Mutation Associated with Responsiveness to Crizotinib.
Waqar SN; Morgensztern D; Sehn J
J Thorac Oncol; 2015 May; 10(5):e29-e31. PubMed ID: 25898962
[No Abstract] [Full Text] [Related]
4. Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET...
Scagliotti GV; Di Maio M
Ann Oncol; 2015 Oct; 26(10):2007-9. PubMed ID: 26265168
[No Abstract] [Full Text] [Related]
5. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
8. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
[TBL] [Abstract][Full Text] [Related]
9. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
11. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
[TBL] [Abstract][Full Text] [Related]
12. Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification.
Cil I; Zirtiloglu A; Saydam N; Tural D
J BUON; 2017; 22(1):279-280. PubMed ID: 28365967
[No Abstract] [Full Text] [Related]
13. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
14. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.
Le Rhun E; Chamberlain MC; Zairi F; Delmaire C; Idbaih A; Renaud F; Maurage CA; Grégoire V
CNS Oncol; 2015; 4(6):381-6. PubMed ID: 26498130
[TBL] [Abstract][Full Text] [Related]
15. Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
Benderra MA; Aspeslagh S; Postel-Vinay S; Bigot L; De Baere T; Loriot Y; Lacroix L; Massard C; Vassal G; André F; Soria JC
J Thorac Oncol; 2016 Feb; 11(2):e21-3. PubMed ID: 26845121
[No Abstract] [Full Text] [Related]
16. Tivantinib in hepatocellular carcinoma.
Trojan J; Zeuzem S
Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
[TBL] [Abstract][Full Text] [Related]
17. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
[TBL] [Abstract][Full Text] [Related]
18. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
19. Tivantinib (ARQ197) in hepatocellular carcinoma.
Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
[TBL] [Abstract][Full Text] [Related]
20. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]